Amyloidosis Symptoms & Treatment

The Bradley Z. Naifeh Amyloidosis Treatment and Research Program at Houston Methodist J.C. Walter Jr. Transplant Center is a world leader in the diagnosis and management of amyloidosis, and our doctors see more cases of amyloidosis than most hospitals across the nation.

 

Amyloidosis is a rare, multisystem disease that develops when abnormally shaped proteins, called amyloid fibrils, are produced in the bone marrow or liver and then deposited in organs or tissue throughout the body, including the heart, kidneys, nerves and gastrointestinal tract. Amyloid fibrils can be deposited in different organs in different people. Over time, buildup of amyloid fibrils leads to organ damage and, ultimately, organ failure.

 

Houston Methodist has one the largest and most successful organ transplant programs in the nation for patients with amyloidosis. For patients with advanced organ failure, we offer single-organ, multi-organ and bone marrow transplants.

 

Collaborative, Cutting-edge Amyloidosis Care

 

At Houston Methodist, our amyloid program includes experts across many different specialties, including cardiology, gastroenterology, hepatology, hematology, pulmonology, neurology, nephrology and transplant surgery.

 

By combining quick and efficient diagnosis with advanced care, our experts ensure that patients receive the most effective treatment options as early as possible. Our goal is to diagnose and treat amyloidosis before it leads to life-threatening organ failure.

 

Expertise in Organ Transplant for Amyloidosis

 

If irreversible organ failure is present, our team has extensive experience performing bone marrow transplants as well as solid organ transplants, including heart, liver, kidney, lung and multi-organ transplants. Our experts are also leading the development of innovative transplant strategies to treat complex amyloidosis cases more effectively.

About Amyloidosis

3rd Annual Bradley Z. Naifeh Amyloidosis Conference

Amyloidosis is an underrecognized condition because it has historically been misconceived to be a rare disease and presents in a myriad of clinical situations in a subtle manner. Recent advances in therapeutics have made it imperative that this condition is recognized and categorized appropriately in a timely manner so that individuals can get access to appropriate care. Due to a systemic nature of amyloid, various subspecialities are on the fore front of battling this disease. The goal of the Bradley Z. Naifeh Amyloidosis Conference is to create a faculty panel from various disciplines to engage in the mission to promote awareness and educate attendees on Amyloidosis in a comprehensive manner. Learn more about our 3rd annual event here

Amyloidosis Patient Stories

Amyloidosis experts at Houston Methodist have helped many people — from Houston as well as throughout the nation — suffering from amyloidosis. Here are a few of their stories.

 

Don's Story

As a groundbreaking shooting guard and former coach of the Houston Rockets, Don Chaney, has taken on many challenges. Now, he’s taking on amyloidosis. Read Don’s story.

 

Walt's Story

Three years after amyloidosis left him needing a multi-organ transplant, Walt McGuire ran a 400 meter race at the Transplant Games of America. Read Walt's story.

 

Vernon's Story

Vernon Roberson’s TTR amyloidosis left him needing a multi-organ transplant. Through a rare procedure called a domino transplant, Roberson received a new heart and liver. Read Vernon’s story.

DeBakey CV Live: Livestream Recording

Learn from our experts about how to distinguish between AL and TTR amyloidosis, including how to diagnose TTR with PYP testing, and new emerging treatments for TTR cardiomyopathy. 

Publications

Delayed autologous stem cell transplant following cardiac transplantation experience in patients with cardiac amyloidosis. Learn more.